R. Lorente

发表

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

P. Nos, D. Ginard, L. Pérez-Méndez, 2021, Gastroenterología y Hepatología.

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

J. Gisbert, F. Rodríguez‐Artalejo, E. Torrella, 2019, Therapeutic advances in gastroenterology.

Epidemiology and temporal trends (2000–2012) of inflammatory bowel disease in adult patients in a central region of Spain

A. Lucendo, Á. Arias, S. González-Castillo, 2014, European journal of gastroenterology & hepatology.

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

C. Taxonera, R. Ferreiro-Iglesias, M. Calvo, 2021, Therapeutic advances in gastroenterology.

Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease.

E. Laserna-Mendieta, A. Lucendo, Á. Arias, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients.

A. Lucendo, Á. Arias, C. Verdejo, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

J. Gisbert, M. Piqueras, M. Andreu, 2018, Alimentary pharmacology & therapeutics.

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry

J. Gisbert, F. Rodríguez‐Artalejo, X. Calvet, 2017, The American Journal of Gastroenterology.

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

J. Gisbert, X. Calvet, M. Chaparro, 2016, Inflammatory bowel diseases.

Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

J. Gisbert, X. Calvet, M. Piqueras, 2022, Frontiers in Medicine.

Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

J. Gisbert, X. Calvet, M. Piqueras, 2021, Journal of Crohn's & colitis.

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

J. Gisbert, X. Calvet, M. Piqueras, 2020, Digestive Diseases and Sciences.

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.

J. Gisbert, X. Calvet, M. Dominguez-Cajal, 2019, Inflammatory bowel diseases.

EFFECTIVENESS AND SAFETY OF THE SEQUENTIAL USE OF A SECOND AND THIRD ANTI-TNF AGENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY SHORT TITLE: Sequential use of anti-TNFs in IBD patients AUTHORS

Mariana, J. Gisbert, X. Calvet, 2020 .

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

P. Nos, D. Ginard, L. Pérez-Méndez, 2022, Gastroenterología y Hepatología (English Edition).

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.

J. Gisbert, X. Calvet, D. Bernardo, 2019, Journal of Crohn's & colitis.

Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.

J. Olmedo, R. Paton, F. Domper, 2009, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.

M. J. Cabello, J. Gisbert, D. Busquets, 2022, Digestive and Liver Disease.

Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease

A. Lucendo, Á. Arias, C. Verdejo, 2018, European journal of gastroenterology & hepatology.

P744 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU

J. Gisbert, F. Rodríguez‐Artalejo, E. Torrella, 2020 .

P790 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU

J. Gisbert, F. Rodríguez‐Artalejo, E. Torrella, 2019, Journal of Crohn's and Colitis.

P276 Influence of vedolizumab on extraintestinal manifestations in Inflammatory Bowel Disease: a nationwide multicenter study of the GETECCU Eneida registry

J. Gisbert, M. Chaparro, A. Algaba, 2021 .

Endoscopic follow-up of gastric ulcer in a population at intermediate risk for gastric cancer.

A. Albillos, P. Carpintero, J. Olmedo, 2009, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry

D. Busquets, M. Martín-Arranz, M. Iborra, 2020, Journal of Crohn's and Colitis.

Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

F. García-Alonso, F. Mesonero, A. Castaño-García, 2024, Therapeutic advances in gastroenterology.